https://www.selleckchem.com/pr....oducts/pyrrolidinedi
However, there was no significant difference in OS between PD (progressive disease) patients with and without HPD ( =0·05). We identified three clinical variables as risk factors for HPD, providing an opportunity to aid the pre-treatment evaluation of the risk of HPD in patients treated with immunotherapy. This study was funded by the National Natural Science Foundation of China (81571664, 81871323, and 81801665); National Natural Science Foundation of Guangdong Province (2018B030311024); Scientific R
Like
Comment
Share
